The next break­through? MSK’s Sade­lain ties up with Fate on off-the-shelf CAR-Ts

Fate Ther­a­peu­tics is team­ing up with one of the star sci­en­tists at Memo­r­i­al Sloan Ket­ter­ing to start work on off-the-shelf T cell ther­a­pies, one of the hottest fields in the next-gen CAR-T field.

This morn­ing the San Diego-based biotech an­nounced that it will part­ner with Michel Sade­lain, a key sci­en­tist at MSK who has played a promi­nent role in de­vel­op­ing Juno’s per­son­al­ized CAR-Ts.

To get start­ed, Fate has in-li­censed tech that cen­ters on en­gi­neer­ing pluripo­tent cell lines to make them ef­fec­tive for all tar­get­ed pa­tients. The first wave of CAR-Ts cen­ters on per­son­al­ized ther­a­peu­tics in which in­ves­ti­ga­tors ex­tract im­mune T cells from pa­tients, arm them with chimeric anti­gen re­cep­tors and then in­fuse them back in­to the pa­tient to hunt down can­cer cells. That ap­proach has proved par­tic­u­lar­ly ef­fec­tive for the front-wave hema­to­log­ic pro­grams now in the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.